冯晓明,教授,现任职于杭州师范大学基础医学院免疫与病原生物学系。曾任职中国医学科学院血液病医院研究员、博士生导师。长期从事T细胞的基础和应用研究,首次发现Foxp1、Lkb1等T细胞关键调节分子,并与临床合作首创多种治疗白血病的新型T细胞免疫治疗方法。以第一或共同完成人获美国Wistar研究所Ching Jer Chern Memorial Award、中国医院协会科技创新三等奖、福建医学科技奖一等奖等荣誉。以通讯或第一作者在Nat Med, Lancet Oncology, J Clin Oncol、Nat Immunol等期刊发表论文50余篇。曾获海外高层次人才引进计划青年项目(2013)、国家自然科学基金优秀青年科学基金(2014)、天津市杰出青年科学基金(2017)等重要人才计划。
教育背景
1. 2008.05-2012.01 美国Wistar研究所 免疫学 博士后
2. 2003.09-2008.05 北京协和医学院 内科学 博士学位
3. 1998.09-2003.07 华中科技大学同济医学院 临床医学 学士学位
主要工作简历
1. 2024.10至今 杭州师范大学基础医学院 免疫与病原生物学系 教授
2. 2012.02-2024.09 中国医学科学院血液病医院 免疫学以及干细胞与再生医学专业 独立PI/研究员
主持科研项目
1. 2021-2026 国家重点研发计划项目 人干细胞向调节型和效应型免疫细胞的分化与功能优化研究(2021YFA1100703) 950万 在研 主持子课题
2. 2022-2025 主持国家自然科学基金面上项目 SUB1调控Treg细胞异质性分化及功能特化的作用与机制研究(32170891)56万 在研 主持
3. 2019-2022 国家自然科学基金面上项目 Lkb1维持Treg细胞稳定性对正常与GVHD情况下造血干细胞自稳的调控作用,(81870090) 60万 在研 主持子课题
4. 2017-2021 天津市杰出青年科学基金项目 调节性T细胞谱系稳定性的控制机制研究 (17JCJQJC4580)100万 结题 主持
5. 2015-2019国家重大科学研究计划项目 骨髓微环境中关键免疫调节细胞对移植HSC存活和功能的调控作用及机制研究(2015CB964402)230.48万 结题 主持子课题
6. 2014-2016国家自然科学基金优秀青年项目 T淋巴细胞发育与功能 (81322007)100万 结题 主持
代表性论著(*通讯作者或责任作者;#第一作者)
1. Pan J*, Tan Y, Shan L, Seery S, Deng B, Ling Z, Xu J, Duan J, Wang Z, Wang K, Yu X, Zheng Q, Xu X, Hu G, Tan T, Yuan Y, Tian Z, Yan F, Han Y, Zhang J, Feng X*. Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial. Nat Med 2024 Oct 1. doi: 10.1038/s41591-024-03282-2.
2. Zhao L, Li C, Zuo S, Han Y, Deng B, Ling Z, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Tian Z, Tang K, Zhang Y, Niu Q, Zhang J, Chang AH, Luo Y*, Feng X*, Pan J*. Autologous CD7 CAR T cells generated without T-cell pre-selection in pediatric patients with relapsed/refractory T-ALL: a phase I trial. Mol Ther 2024:S1525-0016(24)00594-X.
3. Zuo S, Li C, Sun X, Deng B, Zhang Y, Ling Z, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Tian Z, Shan L, Tang K, Huang H, Wang G, Wu T, Pan J, Feng X*. C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial. Nat Commun 2024;15(1):6155.
4. Niu Q, Luo Y, Zhang H, He B, Jiang E, Feng X*. GSNOR overexpression enhances CAR-T stemness and anti-tumor function by enforcing mitochondrial fitness. Mol ther 2024;32(6):1875-1894.
5. Pan J#, Tang K#, Luo Y#, Seery S, Tan Y, Deng B, Liu F, Xu X, Ling Z, Song W, Xu J, Duan J, Wang Z, Li C, Wang K, Zhang Y, Yu X, Zheng Q, Zhao L, Zhang J, Chang AH, Feng X#. Sequential CD19 and CD22 CAR T-Cell Therapy for Childhood Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Phase II Study. Lancet Oncol 2023;24:1229-41. (See comments in Lancet Oncol 2023;24:1163-4; Blood Sci. 2024 Jan 10;6(1):e00177).
6. Tan Y, Shan L, Zhao L, Deng B, Ling Z, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Yu X, Tian Z, Zhang Y, Zhang J, Chang AH*, Feng X*, Pan J*. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol 2023,16(1):34.
7. Wang G, Sun X, Zuo S, Li C, Niu Q, Xia Y, Meng Y, Liu M, Fang Z, Yang X, Jiang Y, Wang S, Cui H, Huang H, Jiang E, Zhou D, Deng Q*, Pan J*, Feng X*. Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia. J Hematol Oncol 2021,14(1):149.
8. Pan J*, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH*, Feng X*. Donor-Derived CD7 CAR T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in Human, Phase I Trial. J Clin Oncol 2021,39(30):3340-3351. (ESI highly cited paper; See comment in Nat Rev Clin Oncol 2021.544.168)
9. Luo Y, Xu C, Wang B, Niu Q, Su X, Bai Y, Zhu S, Zhao C, Sun Y, Wang J, Liu M, Sun X, Song G, Cui H, Chen X, Huang H, Wang H, Han M*, Jiang E*, Shi L*, Feng X*. Single-cell transcriptomic analysis reveals disparate effector differentiation pathways in human Treg compartment. Nat Commun 2021,12:3913.
10. Tan Y, Cai H, Li C, Deng B, Song W, Ling Z, Hu G, Yang Y, Niu P, Meng G, Cheng W, Xu J, Duan J, Wang Z, Yu X, Feng X*, Zhou J*, Pan J*. A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL. Blood Cancer J 2021,11:71.
11. Pan J*, Tan Y, Deng B, Tong C, Hua L, Ling Z, Song W, Xu J, Duan J, Wang Z, Guo H, Yu X, Chang AH, Zheng Q*, Feng X*. Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children. Leukemia 2020,34:3382-7.
12. Pan J*, Zuo S, Deng B, Xu X, Li C, Zheng Q, Ling Z, Song W, Xu J, Duan J, Wang Z, Yu X, Chang AH*, Feng X*, Tong C*. Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL. Blood 2020,135:387-91. (ESI highly cited paper; see comment in Blood 2020,135:303-4)
13. Su X, Wang Q, Guo W, Pei X, Niu Q, Liu M, Liu Y, Chen S, Feng S, Yi He, Yang D, Zhang R, Ma Q, Zhai W, Pang A, Wei J, Huang Y, Luo Y, Han M*, Feng X*, Jiang E*. Loss of Lkb1 impairs Treg function and stability to aggravate graft-versus-host disease after bone marrow transplantation. Cell Mol Immunol 2020,17:483-95.
14. Pan J, Niu Q, Deng B, Liu S, Wu T, Gao Z, Liu Z, Zhang Y, Qu X, Zhang Y, Liu S, Ling Z, Lin Y, Zhao Y, Song Y, Tan X, Zhang Y, Li Z, Yin Z, Chen B, Yu X, Yan J, Zheng Q, Zhou X, Gao J, Chang AH*, Feng X*, Tong C*. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia 2019,33:2854-66. (ESI highly cited paper)
15. Chen S, Fang L, Guo W, Zhou Y, Yu G, Li W, Dong K, Liu J, Luo Y, Wang B, Li Z, Zhao C, Sun Z, Shen Y, Leng Q, Zhou D, Han Z, Huang H, Ren H*, Xu G*, Feng X*. Control of Treg cell homeostasis and immune equilibrium by Lkb1 in dendritic cells. Nat Commun 2018,9:5298. (See comment in Cell Res 2019;29:429-31)
16. Wu D, Luo Y, Guo W, Niu Q, Xue T, Yang F, Sun X, Chen S, Liu Y, Liu J, Sun Z, Zhao C, Huang H, Liao F, Han Z, Zhou D, Yang Y, Xu G, Cheng T*, Feng X*. Lkb1 maintains Treg cell lineage identity. Nat Commun 2017,8:15876.
17. Feng X#, Wang H#, Takata H, Day TJ, Willen J, Hu H. Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat Immunol 2011,12:544-50. (Article of the month; see comment in Nat Immunol 2011,12:522-4)
18. Feng X#, Ippolito GC#, Tian L#, Wiehagen K, Oh S, Sambandam A, Willen J, Bunte RM, Maika SD, Harriss JV, Caton AJ, Bhandoola A, Tucker PS, Hu H. Foxp1 is an essential transcription regulator for the generation of quiescent naive T cells during thymocytes development. Blood 2010,115:510-8.